DefiniGEN

Recent Finacing

Equity

Recent Raise

Undisclosed

DefiniGEN operates the OptiDIFF iPSC platform to produce gene-edited, high-functionality liver, pancreatic and lung cells (including cryopreserved beta cells) as predictive in vitro models for pharmaceutical R&D.